


Anabolic Lab™

Analytical Lab Testing for
Anabolic Steroid Harm Reduction

<https://anaboliclab.com>

Lab Report – August 11, 2017

Alpha Pharma Healthcare
Rexogin (50 mg/mL)
Stanozolol



If you like the attached report, please visit [our website](https://anaboliclab.com) to find out how you can support independent and objective lab testing.



Simec AG

Gärtnereweg 4 B CH-4665 Oftringen
Telefon +41 62 752 83 08 Fax +41 62 752 83 09
E-Mail: info@simec.ch www.simec.ch

Test report

Number **C 57939**

Object of analysis: Rexogin, Alpha Pharma

Customer: AnabolicLab.com

Samples: 1

Batch: RX1505

Receipt: 23.06.2017



Subject: Content, Identification Stanozolol

Method(s): HPLC, SOP M 006

Sample / Analysis:	Method	Status	Result	Specification	complies
<u>Stanozolol:</u>					
Identification	HPLC	N	complies	complies	yes
Content	HPLC	N	41.1 mg/mL	50 mg/mL	-
TAMC	SOP M 006	N	< 1 KBE/mL	-	-
TYMC	SOP M 006	N	< 1 KBE/mL	-	-

Method-status: G = GMP A = accredited V = generally validated P = validated on product N = not validated
E = external lab

Remarks: The sample(s) mentioned above have been analysed as they have been sent to us by the client. We have not controlled external processes like manufacturing, labelling, sampling, shipping, storage. These results are for information only and do not compensate for correct quality control by the manufacturer/distributor. Generally, pharmaceutical products have to be produced and distributed under full GMP/GDP regime, including GMP-compliant analyses with validated methods. It is not allowed to use this analysis in the context of doping/sports/competitions or any other illegal action, neither by the athlete nor by the tutor/trainer or any other person.

Signatures: controlled & released:  **Staff:** 

completed:
11.08.2017

The enclosed results refer exclusively to the object of examination described above. The measuring accuracy is available on request. Only handwritten signatures are valid. Without written permission, it is not allowed to publish single parts of this report.